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Dr. Yu Fang is an associate professor in the Department of Pharmacy Administration at the School 
of Medicine, Xi’an Jiaotong University.  Dr. Fang’s research interests focus on assessing the 
accessibility of essential prescription drugs in western China and evaluating outcomes of 
pharmaceutical care for patients with hypertension.  Dr. Fang has published multiple peer-reviewed 




Kun Zhang is a Prevention Effectiveness Fellow at the Centers for Disease Control and Prevention 
张坤博士是美国疾病控制与预防中心研究员。 
 
Kun: What aspects of the CMB Open Competition (OC) grant you find the most appealing? 
张坤：CMB 公开竞标项目的哪些方面吸引了你的参与？ 
 
Dr. Fang: What appeals to me the most is the purpose and theme of the CMB OC, which is to 
improve health policy and systems sciences (HPSS) research capacity in China through 
supporting researchers in medicine and public health across China.  Second, CMB OC 
emphasizes emerging health challenges and the new healthcare reform in China, and it is 
willing to fund research in these areas to ensure that people in China have equitable access to 
healthcare.  Third, CMBOC provides young researchers in China a great platform for 






Kun: Are there any lessons learned from  participating in the CMB OC? 
张坤：这次申请 CMB 公开竞标项目过程中，哪些经验对你最重要？ 
 
Dr. Fang: The application for CMB Open Competition grant led to many new ideas for me when 
searching for research topics and carrying out HPSS studies.  Moreover, in the second round of 
the review process, the reviewers provided constructive comments on study design, data 
collection, feasibility of the proposal, and the budget planning.  These comments are extremely 
helpful to my future research and grant writing.  I truly appreciate the effort and contribution of 








Kun: As an expert in pharmaceutical policy research, what do you think are the major causes for 
the high price of pharmaceutical products in China? 
张坤：作为一位药物政策研究领域的专家，你认为目前我国药价高的主要原因是什么？ 
 
Dr. Fang: In my opinion, the long-standing public hospitals' reliance on drug sales to generate 
revenue is the main reason of the high price of pharmaceutical products in China.  In 2009, 
national health care expenditure in China totaled $240 billion, about 5% of China’s gross 
domestic product (GDP). Spending on drugs accounted for more than 40% of total expenditure, 
which is one of the highest in the world.  The high pharmaceutical expenditure is associated with 
both high retail prices of drugs and high utilization, some of which are irrational and 
unnecessary.  Furthermore, both price and utilization factors are deeply associated with policies 
including overall health sector regulation, health care financing policies, and pricing policies. 
Recognizing the major causes for the disproportionately high pharmaceutical expenditure, the 
new round of health care reform particularly emphasized the establishment of National Essential 
Medicines System (NEMS), and the implementation of public hospital reform and promoting 
rational use of medications. 
方宇：公立医院长期依赖药物出售来创造收入是中国药价高的主要原因之一。2009 年，中国的医疗卫生支出达






Kun: What do you think are the pros and cons of establishing a National Essential Medicines system 
by the central government? 
张坤：你认为由政府来制定国家基本药物目录的优势和劣势是什么？ 
 
Dr. Fang: According to the WHO Framework for Action, “access to health care including essential 
medicines is part of the fulfillment of the fundamental right to health.  All countries are obligated 
to work towards the fulfillment of equitable access to health care services and commodities, 
including essential medicines necessary for the prevention and treatment of prevalent diseases.  
Appropriate policies and action plans need to be put in place to achieve this aim".  In response, 
as one of the top five priorities of the Chinese government's systematic plan announced in 2009 
aiming to achieve universal access to healthcare by 2020, the establishment of a NEMS to meet 
basic needs for treatment and prevention and ensure drug safety, quality, and supply was 
particularly emphasized.  I am pretty optimistic that by improving access to existing essential 
medicines in China, more and more people will share the benefits of the healthcare reform.  
Meanwhile, it is urgent to generate evidence about the impact of the NEMS on access to and 
affordability of medicines, as well as to support the central government’s implementation of 






回应。2009 年，中国政府制定了一个系统的计划来保证在 2020 年前实现全民享有医疗卫生服务。这一计划
强调了五个重点领域，其中一个就是建立全国基本药物目录。建立基本药物目录的目的就是保证人民对于
疾病基本的预防的治疗，保障药品安全，质量，以及供给。我本人对于通过改善对基本药物目录药品的获
取使人民最终享有医疗卫生改革的好处保持乐观的态度。同时，我们也亟需相关的研究来评估建立基本药
物目录对于民众用药难用药贵问题的影响，这样才能更好地为中央实施药品政策提供建议与支持。 
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